Endodiabesity

Date: 6th and 7th November 2020

Venue: Virtual Interactive

Organisers: Dr Handrean Soran & Dr Naveed Younis

Course Lead: Dr Handrean Soran (handrean.soran@mft.nhs.uk)

Any enquires please email the course coordinator (ManSce2020@gmail.com)

An example of what the course provides:

• More than 250 new questions will be discussed in 14 sessions covering the whole curriculum.
• Access to another ~120 questions from our pool (mock exams included).
• Focus on clinically relevant areas and popular exam topics.
• Speaker’s predictions on potential areas of interest.
• An overall update in endocrinology and diabetes.

Who should attend?

SpRs in Endocrinology and Diabetes, CMTs who plan a career in Endocrinology and Diabetes, Chemical Pathology and Metabolic Medicine trainees, any other UK based or overseas trainee or HCP who is intending to have a career in Diabetes and Endocrinology and/or planning to take the SCE exam or to improve his/her knowledge in Endocrinology and Diabetes. Primary care physicians/trainees and overseas doctors are welcome. The course provides an extensive review and update of all the Endocrinology and Diabetes curriculum.

To reserve your place:

• Complete the Registration Form.
• Payment £250.00 before 14th October 2020 (£300 after 14th October 2020): payable via below PayPal account. Please make sure you send your payment once you finish the registration to receive the confirmation . NO confirmation will be sent without receiving the payment.
• Cancellation policy: registration fee is not refundable if cancellation after 26th October 2020.
• Only 40 Places are available. First come, first served. Registration will close on 26th October 2020.
• The link to the online interactive programme will be emailed to the delegates one week in advance. The link allows only one person to join. No other people should be present except the delegate.
• Delegates should keep the camera open all the time during the course to allow best interaction. If the camera is closed or other conditions breached the delegate may be blocked.

Obesity is an emerging independent risk factor for susceptibility to and severity of coronavirus disease 2019 (COVID‐19) caused by the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). Previous viral pandemics have shown that obesity, particularly severe obesity (BMI > 40 kg/m²), is associated with increased risk of hospitalization, critical care admission and fatalities. In this narrative review, we examine emerging evidence of the influence of obesity on COVID‐19, the challenges to clinical management from pulmonary, endocrine and immune dysfunctions in individuals with obesity and identify potential areas for further research. We recommend that people with severe obesity be deemed a vulnerable group for COVID‐19; clinical trials of pharmacotherapeutics, immunotherapies and vaccination should prioritize inclusion of people with obesity.

https://onlinelibrary.wiley.com/doi/full/10.1111/cob.12403

© 2020 The Authors. Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Obesity: A critical risk factor in the COVID‐19 pandemic
"…viral pandemics have shown that obesity, particularly severe obesity (BMI > 40 kg/m2), is associated with increased risk of hospitalization, critical care admission and fatalities."
https://t.co/m8CMELCdrQ pic.twitter.com/aOmdkdYQhL

— aͥkheͣeͫl syed (@AkheelSyed) August 28, 2020

Dear all, hope you have managed to register for the clinical webinars from the summer series of the Society For Endocrinology.

The next topic is on Adreno-cortical tumours. This is an excellent way for those in the training pathway as well as non trainees to update their knowledge on this topic.

Date – 12 August 2020 5:30 pm to 6:30 pm

A viewpoint published in the BMJ today which briefly reviews the hidden risks that obesity poses in relation to COVID-19.

New publication from the region in Atherosclerosis which covers a commonly encountered conundrum in clinical practice. The article can be accessed via this link.

Following on from the discussion after the case presentation by Dr Bashir at the clinical cases meeting on Wednesday, please find a useful article published in 2017 by Chin et al. – the full article (PDF) is available from the Journal of the Royal College of Physicians of Edinburgh.